Clay Siegall Explains the Plans of Seattle Genetics, Including ADCs

Clay Siegall is a brilliant cancer researcher and a visionary entrepreneur with great success in both the roles. As the founder and Chief Executive of the biotechnology firm, Seattle Genetics, he revolutionized the cancer research and showcased how a pharma firm should be set up. Under his leadership, the company has got increased attention from the industry leaders, and people are waiting for his solutions. While coming to the firm, it’s flagship drug, Adcetris, provides highly positive results when used to treat Hodgkin lymphoma – a type of cancer that affects the lymph system.

Apart from the flagship drug, there are more than a dozen of drugs in the pipeline from Seattle Genetics. Clay Siegall confirms that the company is growing as a multiproduct, global, oncology company with its research and effective treatment solutions. He is very optimistic and passionate about advancing the research, expanding the market, and more. Recently, Seattle Genetics opened an office and research lab in Switzerland as part of international marketing efforts. Siegall also tried to acquire a cancer drug by bidding $2 billion from Immunomedics – a New Jersey-based drugmaker.

Under the leadership of Siegall, the company is focused on producing ADCs or antibody-drug conjugates. Interestingly, these drugs are designed to target the antigens. ADCs attach to the disease cells and pumps toxins into them to kill without creating any trouble to healthy cells. Due to that reason, many scientists hail ADCs as “smart bombs” considering its effectiveness in killing cancer cells. Considering the healthy cell damage while using the radiation and chemotherapy, ADCs are expected to make a revolution in the market due to the efficient recovery of patients.

Dr. Siegall co-founded the firm in 1998 and led it as its Chief Executive Officer from then. Apart from guiding the research works of Seattle Genetics, he is also the leading strategist in the capital-raising process for the firm. Currently, it has 900 employees and a market value of more than $10 billion. Dr. Siegall is accelerating the research efforts of the company, and he has already laid out plans to hire 200 more employees to expand the marketing and research efforts of the firm.

Before establishing Seattle Genetics, Dr. Siegall was working for Bristol-Myers Squibb Research Institute and the reputed National Cancer Institute. While coming to the education, he completed his graduation in Zoology from the University of Maryland and earned his Ph.D. from George Washington University in Genetics.